Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood–Brain Barrier Using Elacridar and 11C-Erlotinib PET

Remy B. Verheijen; Maqsood Yaqub; Emilia Sawicki; Olaf van Tellingen; Adriaan A. Lammertsma; Bastiaan Nuijen; Jan H.M. Schellens; Jos H. Beijnen; Alwin D.R. Huitema; N. Harry Hendrikse; Neeltje Steeghs

doi:10.2967/jnumed.117.195800

Research ArticleRadiochemistry

Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood–Brain Barrier Using Elacridar and ¹¹C-Erlotinib PET

Remy B. Verheijen, Maqsood Yaqub, Emilia Sawicki, Olaf van Tellingen, Adriaan A. Lammertsma, Bastiaan Nuijen, Jan H.M. Schellens, Jos H. Beijnen, Alwin D.R. Huitema, N. Harry Hendrikse and Neeltje Steeghs

Journal of Nuclear Medicine June 2018, 59 (6) 973-979; DOI: https://doi.org/10.2967/jnumed.117.195800

Remy B. Verheijen

1Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute–Antoni van Leeuwenhoek, Amsterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Maqsood Yaqub

2Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Emilia Sawicki

1Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute–Antoni van Leeuwenhoek, Amsterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Olaf van Tellingen

3Department of Bio-Pharmacology/Mouse Cancer Clinic, The Netherlands Cancer Institute–Antoni van Leeuwenhoek, Amsterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Adriaan A. Lammertsma

2Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Bastiaan Nuijen

1Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute–Antoni van Leeuwenhoek, Amsterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jan H.M. Schellens

4Department of Clinical Pharmacology and Medical Oncology, The Netherlands Cancer Institute–Antoni van Leeuwenhoek, Amsterdam, The Netherlands

5Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jos H. Beijnen

1Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute–Antoni van Leeuwenhoek, Amsterdam, The Netherlands

5Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alwin D.R. Huitema

1Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute–Antoni van Leeuwenhoek, Amsterdam, The Netherlands

6Department of Clinical Pharmacy, Utrecht University Medical Center, Utrecht, The Netherlands; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

N. Harry Hendrikse

2Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands

7Department of Clinical Pharmacology and Pharmacy, VU University Medical Center, Amsterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Neeltje Steeghs

4Department of Clinical Pharmacology and Medical Oncology, The Netherlands Cancer Institute–Antoni van Leeuwenhoek, Amsterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 59, Issue 6

June 1, 2018

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood–Brain Barrier Using Elacridar and 11C-Erlotinib PET

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood–Brain Barrier Using Elacridar and ¹¹C-Erlotinib PET

Journal of Nuclear Medicine Jun 2018, 59 (6) 973-979; DOI: 10.2967/jnumed.117.195800

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood–Brain Barrier Using Elacridar and ¹¹C-Erlotinib PET

Journal of Nuclear Medicine Jun 2018, 59 (6) 973-979; DOI: 10.2967/jnumed.117.195800

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

This Month in JNM

PubMed
Google Scholar

Cited By...

ABCG2- and ABCB1 Inhibition Using Supratherapeutic Doses of Erlotinib: Clinical Implications in the Treatment of Central Nervous System Metastases
A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier

Google Scholar

Radiochemistry

Cyclotron-Produced ¹³²La as a PET Imaging Surrogate for Therapeutic ²²⁵Ac
Cyclotron Production and Separation of Scandium Radionuclides from Natural Titanium Metal and Titanium Dioxide Targets
Synthesis of the PET Tracer ¹²⁴I-Trametinib for MAPK/ERK Kinase Distribution and Resistance Monitoring

Show more Radiochemistry

Clinical

Tau^IQ: A Canonical Image Based Algorithm to Quantify Tau PET Scans
Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker
Addition of ¹³¹I-MIBG to PRRT (⁹⁰Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors

Show more Clinical

Keywords

Erlotinib
Elacridar
blood–brain barrier
PET
molecular imaging

Main menu

User menu

Search

Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood–Brain Barrier Using Elacridar and ¹¹C-Erlotinib PET

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Radiochemistry

Clinical

Similar Articles

Keywords